Bildkälla: Stockfoto

Bioservo Q2’22: Inflection point delayed - Redeye

Redeye reduces our short-to mid-term estimates due to a lower estimated number of systems to be sold during 2023E and, to an extent, into 2024E. The estimate changes and new issues alter our Base Case to SEK 8 per share. We still see a compelling long-term case; however, the commercialization of Ironhand has taken longer than we expected.

Redeye reduces our short-to mid-term estimates due to a lower estimated number of systems to be sold during 2023E and, to an extent, into 2024E. The estimate changes and new issues alter our Base Case to SEK 8 per share. We still see a compelling long-term case; however, the commercialization of Ironhand has taken longer than we expected.
Börsvärldens nyhetsbrev
ANNONSER